Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
This study has been completed.
First Posted: November 5, 2007
Last Update Posted: August 8, 2014
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2014|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||November 15, 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275.